Signpath Pharma, Inc. (SGTH) financial statements (2021 and earlier)

Company profile

Business Address 3477 CORPORATE PARKWAY, SUITE 100
CENTER VALLEY, PA 18034
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6417936924986661,043716
Cash and cash equivalents6417936924986661,043716
Prepaid expense2357   
Total current assets:6427966985056661,043716
Noncurrent Assets
TOTAL ASSETS:6427966985056661,043716
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:283236310303328317448
Accrued liabilities868686   75
Interest and dividends payable2,1451,9371,7301,5301,336  
Other undisclosed accounts payable and accrued liabilities(1,948)(1,786)(1,506)(1,227)(1,008)317373
Total current liabilities:283236310303328317448
Noncurrent Liabilities
Total liabilities:283236310303328317448
Stockholders' equity
Stockholders' equity attributable to parent, including:359560388202338726268
Common stock14141414141414
Common stock, share subscribed but unissued, subscriptions receivable (16)(249)    
Additional paid in capital14,33014,07013,94413,43613,29013,42612,700
Accumulated deficit(16,131)(15,446)(15,052)(14,780)(14,303)(13,862)(13,417)
Warrants and rights outstanding     12,78615,699
Other undisclosed stockholders' equity attributable to parent2,1471,9381,7311,5321,337(11,639)(14,729)
Total stockholders' equity:359560388202338726268
TOTAL LIABILITIES AND EQUITY:6427966985056661,043716

Income statement (P&L) ($ in thousands)

6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Revenue, net 75(75)    
Financial services revenue  30    
Other income  0 5 
Gross profit: 75(45) 5  
Operating expenses(683)(396)(271)(476)448452(606)
Other undisclosed operating income (loss) (75)45 (901)(904) 
Operating loss:(683)(396)(271)(476)(448)(452)(606)
Nonoperating income (expense)(2)211(3)97(3)
Foreign currency transaction gain (loss), before tax  11(1)2  
Other nonoperating income (expense)(2)2(0)(1)77(3)
Loss from continuing operations before equity method investments, income taxes:(686)(394)(260)(479)(439)(445)(608)
Other undisclosed income (loss) from continuing operations before income taxes  (11)1(2)(0)(0)
Net loss attributable to parent:(686)(394)(272)(477)(441)(445)(609)
Other undisclosed net loss available to common stockholders, basic(209)(207)(199)(195)(189)  
Net loss available to common stockholders, diluted:(894)(601)(471)(672)(630)(445)(609)

Comprehensive Income ($ in thousands)

6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Net loss:(686)(394)(272)(477)(441)(445)(609)
Comprehensive loss, net of tax, attributable to parent:(686)(394)(272)(477)(441)(445)(609)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: